Nedosiran Explained

Tradename:Rivfloza
Dailymedid:Nedosiran
Routes Of Administration:Subcutaneous
Atc Prefix:None
Legal Us:Rx-only
Legal Us Comment:[1]
Cas Number:2266591-83-5
Drugbank:DB17635
Unii:13U9R5J3WL
Synonyms:DCR-PHXC

Nedosiran, sold under the brand name Rivfloza, is a medication used for the treatment of primary hyperoxaluria. It is an LDHA-directed small interfering RNA developed by Dicerna Pharmaceuticals.[2]

The most common side effects include injection site reactions.

Nedosiran was approved for medical use in the United States in September 2023.[3] [4] [5] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[6]

Medical uses

Primary hyperoxaluria type 1 is a rare disease in which urine oxalate is too high, which over time can harm the kidneys.

Nedosiran is indicated to lower urinary oxalate levels in people nine years of age and older with primary hyperoxaluria type 1 and relatively preserved kidney function.

History

The US FDA approved nedosiran based on evidence from a clinical trial which included 29 participants with primary hyperoxaluria type 1. Nedosiran was evaluated in one clinical trial of 29 participants with primary hyperoxaluria type 1 who were nine years of age and older. Participants randomly received either nedosiran or placebo injections once a month for six months. Neither the participants nor the healthcare providers knew which treatment was being given. The benefit of nedosiran was assessed by measuring the amount of oxalate in the urine and comparing it to placebo. The trial was conducted at 19 sites in 11 countries in North America, Europe, Asia, and Australia.

Society and culture

Legal status

The FDA granted the application for nedosiran breakthrough therapy and orphan drug designations. Nedosiran was approved for medical use in the United States in September 2023.

Names

Nedosiran is the international nonproprietary name.[7]

Further reading

Notes and References

  1. Web site: Rivfloza (nedosiran) injection, for subcutaneous use . 1 October 2023 . 1 October 2023 . https://web.archive.org/web/20231001235147/https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215842s000lbl.pdf . live .
  2. Web site: Nedosiran . Dicerna Pharmaceuticals . 17 August 2021 . 1 October 2023 . 26 July 2023 . https://web.archive.org/web/20230726061616/https://dicerna.com/pipeline/nedosiran/ . live .
  3. Web site: Rivfloza: FDA-Approved Drugs . U.S. Food and Drug Administration (FDA) . 1 October 2023 . 2 October 2023 . https://web.archive.org/web/20231002035105/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215842 . live .
  4. Web site: Drug Approval Package: Rivfloza . U.S. Food and Drug Administration (FDA) . 18 October 2023 . 10 January 2024 . 10 January 2024 . https://web.archive.org/web/20240110053505/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215842Orig1s000TOC.cfm . live .
  5. Web site: Drug Trials Snapshots: Rivfloza . U.S. Food and Drug Administration (FDA) . 29 September 2023 . 15 July 2024.
  6. New Drug Therapy Approvals 2023 . U.S. Food and Drug Administration (FDA) . January 2024 . PDF . 9 January 2024 . https://web.archive.org/web/20240110032419/https://www.fda.gov/media/175253/download . 10 January 2024 . live .
  7. ((World Health Organization)) . 2021 . International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85 . WHO Drug Information . 35 . 1 . 10665/340684 . free . World Health Organization .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nedosiran".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.